SCHEMBL15416183

SCHEMBL15416183

Cc1cn[c]nc1N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
HPGD P15428 1/20 0.41
KHK P50053 1/20 0.41
POLB P06746 1/20 0.40
KDM4E B2RXH2 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
GAA P10253 2/20 0.37
LRRK2 Q5S007 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
USP2 O75604 2/20 0.37
ALOX15 P16050 2/20 0.37
MAPK1 P28482 2/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
CASP7 P55210 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16792277 0.84 KDM4E (0.33) ALDH1A1HPGDKDM4ECYP1A2MAPK1
SCHEMBL16795112 0.84 SMN1; SMN2 (0.37) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL15415930 0.82 SMN1; SMN2 (0.40) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL19410919 0.79 KDM4E (0.44) ALDH1A1POLBKDM4EMEN1KMT2A
SCHEMBL15415122 0.76 POLB (0.46) ALDH1A1HPGDPOLBKDM4EGAA
SCHEMBL15415541 0.76 SLC29A1 (0.39) ALDH1A1HPGDPOLBKDM4EGAA
SCHEMBL15415638 0.72 CYP2A13 (0.44) ALDH1A1POLBKDM4EMEN1KMT2A
SCHEMBL15415615 0.71 NUDT1 (0.41) ALDH1A1HPGDKHKPOLBKDM4E
SCHEMBL22530419 0.71
SCHEMBL16646727 0.70 MEN1 (0.49) ALDH1A1KDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3436456-B1 FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2021-11-17 EP disclosed
EP-3436460-B1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2021-08-18 EP disclosed
EP-3436458-B1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2021-06-02 EP disclosed
US-10953019-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2021-03-23 US disclosed
US-10793578-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2020-10-06 US disclosed
US-10766906-B2 Fused hexacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2020-09-08 US disclosed
US-10669286-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2020-06-02 US disclosed
US-10654861-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity UCB Biopharma SRL (BE) 2020-05-19 US disclosed
US-20190119302-A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity UCB Biopharma SRL (BE) 2019-04-25 US disclosed
US-20190112314-A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity UCB BIOPHARMA SPRL (BE) 2019-04-18 US disclosed
WO-2015086504-A1 IMIDAZOTHIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086502-A1 PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086505-A1 PURINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086513-A1 TETRAHYDROBENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086501-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2872511-A1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 EP disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2014009296-A1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 WO disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA ALDH1A1 317/4885HPGD 1362/4885KHK 2416/4885
US-10953019-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA ALDH1A1 1727/4885HPGD 126/4885KHK 3407/4885
US-10766906-B2 Fused hexacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA ALDH1A1 2149/4885HPGD 129/4885KHK 2487/4885
US-20190119302-A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, NFKBIA ALDH1A1 1788/4885HPGD 208/4885KHK 2523/4885
US-10669286-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA ALDH1A1 1788/4885HPGD 208/4885KHK 2523/4885
US-20190112314-A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, NFKBIA ALDH1A1 1413/4885HPGD 122/4885KHK 3161/4885
US-10654861-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA ALDH1A1 1788/4885HPGD 208/4885KHK 2523/4885
US-10793578-B2 Fused pentacyclic imidazole derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA ALDH1A1 1413/4885HPGD 122/4885KHK 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.